Cited by

• Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

  Green DM, Kun LE, Matthay KK, Meadows AT, Meyer WH, Meyers PA, Spunt SL, Robison LL, Hudson MM. Green DM, et al. Pediatr Blood Cancer. 2013 Jul;60(7):1083-94. doi: 10.1002/pbc.24487. Epub 2013 Feb 15. Pediatr Blood Cancer. 2013. PMID: 23418018 Free PMC article. Review.
• Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

  Bielack SS, Erttmann R, Looft G, Purfürst C, Delling G, Winkler K, Landbeck G. Bielack SS, et al. Cancer Chemother Pharmacol. 1989;24(6):376-80. doi: 10.1007/BF00257446. Cancer Chemother Pharmacol. 1989. PMID: 2676224 Clinical Trial.
• The Current and Future Therapies for Human Osteosarcoma.

  Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH. Lamplot JD, et al. Curr Cancer Ther Rev. 2013 Feb;9(1):55-77. doi: 10.2174/1573394711309010006. Curr Cancer Ther Rev. 2013. PMID: 26834515 Free PMC article.
• Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.

  Meyers PA, Healey JH, Chou AJ, Wexler LH, Merola PR, Morris CD, Laquaglia MP, Kellick MG, Abramson SJ, Gorlick R. Meyers PA, et al. Cancer. 2011 Apr 15;117(8):1736-44. doi: 10.1002/cncr.25744. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472721 Free PMC article. Clinical Trial.
• STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.

  Oi T, Asanuma K, Matsumine A, Matsubara T, Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, Yada Y, Sudo A. Oi T, et al. Int J Oncol. 2016 Dec;49(6):2275-2284. doi: 10.3892/ijo.2016.3757. Epub 2016 Nov 3. Int J Oncol. 2016. PMID: 27840900 Free PMC article.